Encoded Therapeutics secured a $275 million Series F to advance its lead gene therapy ETX101 for Dravet syndrome, targeting infants and children with SCN1A-positive disease. The capital also funds scale-up of internal manufacturing and supports additional program development, including an IND-enabling pathway for ETX301 in neuroma pain. The financing signals investor confidence following interim Phase I/II data presented at the European Epilepsy Congress, where the company reported sustained seizure-frequency reductions and developmental improvements. Alongside ETX101, Encoded is enrolling children in a registration-directed study and expanding to adolescents up to age 18. For the sector, the round underscores how capital markets are increasingly rewarding companies that pair clinical readouts with manufacturing readiness for next-step registrational work.